Background
Bridget works as a Senior Research Officer in the Disease Elimination program, with a specific focus on viral hepatitis projects in low- and middle-income countries. She currently works on the TREAT-HEP Myanmar project and the HepC CUTTS project.
Bridget completed a Bachelor of Arts (International Studies) at RMIT and her honours in Health Sciences through Monash University at the Burnet Institute. Her honours project focussed on acceptability of HIV pre-exposure prophylaxis among men who have sex with men in Myanmar.
In 2022, Bridget completed her PhD exploring how to provide hepatitis C testing and treatment in resource-constrained settings using implementation science and health service delivery research methods. Her work involved evaluating hepatitis C treatment programs in specialist and primary care settings in Myanmar, including the CT2 Study and evaluation of the National Hepatitis Control Program.
Qualifications
- 2022: Doctor of Philosophy, Monash University, Australia
- 2015: Honours (Health Sciences), Monash University, Australia
- 2014: Bachelor of Arts (International Studies), RMIT, Australia
Projects (6)
Current (5)
-
EC Partnership: Eliminate Hepatitis C Partnership
-
Feasibility and Outcomes of the Public Sector Hepatitis C Treatment Program in Myanmar
-
Hepatitis C: Community Testing and Treatment (CT2)
-
SHARP: Sexual Health And Risk Prevention Study
-
The elimination of hepatitis C as a global public health threat
Publications (24)
2022 (4)
- Access to needles and syringes and methadone maintenance therapy among people who inject drugs in Yangon, Myanmar: a qualitative study.
Yee WL, Draper B, Myint KT, Min W, Htay H, O'Keefe D, Hellard M
Harm Reduct J. 2022 Sep; 19(1):107
- Feasibility of decentralised, task-shifted hepatitis C testing and treatment services in urban Myanmar: implications for scale-up.
Draper BL, Yee WL, Shilton S, Bowring A, Htay H, Nwe N, Markby J, Kyi KP, Easterbrook P, Naing W, Win TM, Aung KS, Howell J, Pedrana A, Hellard M
BMJ Open. 2022 May; 12(5):e059639
- The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
Howell J, Traeger MW, Williams B, Layton C, Doyle JS, Latham N, Draper B, Bramwell F, Membrey D, McPherson M, Roney J, Stoové M, Thompson AJ, Hellard ME, Pedrana A
J Viral Hepat. 2022 May; 29(5):375-384
- Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients.
Draper B, Yee WL, Pedrana A, Kyi KP, Qureshi H, Htay H, Naing W, Thompson AJ, Hellard M, Howell J
Lancet Reg Health West Pac. 2022 Mar; 20:100359
2021 (5)
- Health service utilisation and experiences of stigma among people who inject drugs in Melbourne, Australia.
Djordjevic F, Ryan K, Gunn J, Brener L, O'Keefe D, Draper B, Schroeder S, Gold J, Treloar C, Broady T, Dietze P, Hellard M, Pedrana A
J Viral Hepat. 2021 Sep; 28(12):1738-1743
- Outcomes of the CT2 Study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
Draper B, Htay H, Pedrana A, Yee WL, Howell J, Kyi KP, Naing W, Aung KS, Markby J, Easterbrook P, Bowring A, Aung W, Sein YY, Nwe N, Myint KT, Shilton S, Hellard M
Liver Int. 2021 Jun; 41(11):2578-2589
- Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits.
Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi KP, Naing W, Aung KS, Hellard M
Lancet Reg Health West Pac. 2021 May; 10:100129
- Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.
Hellard M, Pedrana A, Draper B
Lancet Gastroenterol Hepatol. 2021 Apr; 6(6):414-416
- In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
Wade AJ, Doyle JS, Draper B, Howell J, Iser D, Roberts SK, Kemp W, Thompson AJ, Hellard ME
J Viral Hepat. 2021 Jan; 28(1):217-218
2020 (5)
- Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study.
Draper BL, Pedrana A, Howell J, Yee WL, Htay H, Aung KS, Shilton S, Kyi KP, Naing W, Hellard M
JMIR Res Protoc. 2020 Jul; 9(7):e16863
- A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
Int J Drug Policy. 2020 Feb; 76:102633
- Prevalence of daily tobacco smoking participation among HIV-positive and HIV-negative Australian gay, bisexual and other men who have sex with men.
Wilkinson A, Quinn B, Draper B, White S, Hellard M, Stoové M
HIV Med. 2020 Feb; 21(2):e3-e4
- Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review.
Cutts JC, Agius PA, Zaw Lin, Powell R, Moore K, Draper B, Simpson JA, Fowkes FJI
BMC Med. 2020 Jan; 18(1):14
- Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Clin Infect Dis. 2020 Jan; 70(9):1900-1906
2019 (1)
- Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A
Int J Drug Policy. 2019 Oct; 72:91-98
2018 (6)
- Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Trials. 2018 Jul; 19(1):383
- Characteristics of men who have sex with men (MSM) and transgender women (TW) in Myanmar who test frequently for HIV.
Veronese V, Min Oo Z, Win Thein Z, Draper B, Aung PP, Ryan C, Thant M, Hughes C, Stoovè M
J Glob Health Rep. 2018 Jul; 2:e2018040
- Measuring and understanding the attitudes of Australian gay and bisexual men towards biomedical HIV prevention using cross-sectional data and factor analyses.
Wilkinson AL, Draper BL, Pedrana AE, Asselin J, Holt M, Hellard ME, Stoové M
Sex Transm Infect. 2018 Jun; 94(4):309-3014
- Comfort Relying on HIV Pre-exposure Prophylaxis and Treatment as Prevention for Condomless Sex: Results of an Online Survey of Australian Gay and Bisexual Men.
Holt M, Draper BL, Pedrana AE, Wilkinson AL, Stoové M
AIDS Behav. 2018 Mar; 22(11):3617-3626
- Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs.
Dietze PM, Draper B, Olsen A, Chronister KJ, van Beek I, Lintzeris N, Dwyer R, Nelson M, Lenton S
Drug Alcohol Rev. 2018 Feb; 37(4):472-479
- Acceptability of Peer-Delivered HIV Testing and Counselling Among Men Who Have Sex with Men (MSM) and Transgender Women (TW) in Myanmar.
Veronese V, Oo ZM, Thein ZW, Aung PP, Draper BL, Hughes C, Ryan C, Pedrana A, Stoové M
AIDS Behav. 2018 Feb; 22(8):2426-2434
2017 (2)
- Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar.
Draper BL, Oo ZM, Thein ZW, Aung PP, Veronese V, Ryan C, Thant M, Hughes C, Stoové M
J Int AIDS Soc. 2017 Jul; 20(1):21885
- A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M
Aust Fam Physician. 2017 Apr; 46(4):235-240
2016 (1)
News Articles (6)
2021 (1)
2020 (1)
2019 (1)
2018 (1)
2017 (1)
2016 (1)
